The Hippo Tumor Suppressor Pathway (YAP/TAZ/TEAD/MST/LATS) and EGFR-RAS-RAF-MEK in cancer metastasis
Open accessThe DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Hippo Tumor Suppressor Pathway is the main pathway for cell growth that regulates tissue enlargement and organ size by limiting cell growth. This pathway is activated in response to cell cycle arrest signals (cell polarity, transduction, and DNA damage) and limited by growth factors or mitogens associated with EGF and LPA. The major pathway consists of the central kinase of Ste20 MAPK (Saccharomyces cerevisiae), Hpo (Drosophila melanogaster) or MST kinases (mammalian) that activates the mammalian AGC kinase dmWts or LATS effector (MST and LATS). YAP in the nucleus work as a cofactor for a wide range of transcription factors involved in proliferation (TEA domain family, TEAD1-4), stem cells (Oct4 mononuclear factor and SMAD-related TGFβ effector), differentiation (RUNX1), and Cell cycle/apoptosis control (p53, p63, and p73 family members). This is due to the diverse roles of YAP and may limit tumor progression and establishment. TEAD also coordinates various signal transduction pathways such as Hippo, WNT, TGFβ and EGFR, and effects on lack of regulation of TEAD cancerous genes, such as KRAS, BRAF, LKB1, NF2 and MYC, which play essential roles in tumor progression, metastasis, cancer metabolism, immunity, and drug resistance. However, RAS signaling is a pivotal factor in the inactivation of Hippo, which controls EGFR-RAS-RAF-MEK-ERK-mediated interaction of Hippo signaling. Thus, the loss of the Hippo pathway may have significant consequences on the targets of RAS-RAF mutations in cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of YAP/TAZ in mechanotransduction
Dupont, S., Morsut, L., Aragona, M., Enzo, E., Giulitti, S., Cordenonsi, M., Zanconato, F., Le Digabel, J., Forcato, M., Bicciato, S., et al. (2011) · Nature · doi:10.1038/nature10137 · Cited by 5,979 · cited 1×
“These sequences, are an 8xGTIIC luciferase plasmid reporter synthetic TEAC luciferase containing 8 GTIIC motifs used to measure YAP/TAZ and TEAD activity.(108) Other transcription factors of TEAD, are more attached to DNA (barely showing transcriptional activity themselves) and are found in the chromatin segment.”
MethodZhao, B., Wei, X., Li, W., Udan, R. S., Yang, Q., Kim, J., Xie, J., Ikenoue, T., Yu, J., Li, L., et al. (2007) · Genes & Development · doi:10.1101/gad.1602907 · Cited by 3,092 · cited 1×
“In animal model experiments, despite the high homology and pattern of expression between TEAD1-4, each TEAD plays different roles in specific tissues (heart, neurodevelopment, tropoderm characterization, and fetal growth) Their most important role in cell biology is the regulation of cell proliferation and contact inh…”
BackgroundTEAD mediates YAP-dependent gene induction and growth control
Zhao, B., Ye, X., Yu, J., Li, L., Li, W., Li, S., Yu, J., Lin, J. D., Wang, C.-Y., Chinnaiyan, A. M., et al. (2008) · Genes & Development · doi:10.1101/gad.1664408 · Cited by 2,498
Hippo pathway in organ size control, tissue homeostasis, and cancer
Yu, F.-X., Zhao, B., & Guan, K.-L. (2015) · Cell · doi:10.1016/j.cell.2015.10.044 · Cited by 2,206
BRAFE600-associated senescence-like cell cycle arrest of human naevi
Michaloglou, C., Vredeveld, L. C. W., Soengas, M. S., Denoyelle, C., Kuilman, T., van der Horst, C. M. A. M., Majoor, D. M., Shay, J. W., Mooi, W. J., & Peeper, D. S. (2005) · Nature · doi:10.1038/nature03890 · Cited by 2,160
RAS oncogenes: weaving a tumorigenic web
Pylayeva-Gupta, Y., Grabocka, E., & Bar-Sagi, D. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3106 · Cited by 1,789 · cited 1×
“The most common oncogenic pathway in different types of tumor is the RAS transduction pathway and also the active mutations responsible for the direct growth and survival signals.(1,92,93) Mutation in all RAS isoforms (K-RAS, H-RAS, and N-RAS) enhances the active form of the protein.”
BackgroundRegulation of the Hippo-YAP Pathway by G-Protein-Coupled Receptor Signaling
Yu, F.-X., Zhao, B., Panupinthu, N., Jewell, J. L., Lian, I., Wang, L. H., Zhao, J., Yuan, H., Tumaneng, K., Li, H., et al. (2012) · Cell · doi:10.1016/j.cell.2012.06.037 · Cited by 1,628
Liu-Chittenden, Y., Huang, B., Shim, J. S., Chen, Q., Lee, S.-J., Anders, R. A., Liu, J. O., & Pan, D. (2012) · Genes & Development · doi:10.1101/gad.192856.112 · Cited by 1,452
Differential regulation and properties of MAPKs
Raman, M., Chen, W., & Cobb, M. H. (2007) · Oncogene · doi:10.1038/sj.onc.1210392 · Cited by 1,430 · cited 1×
“Thus, the mitogen-activated protein kinase cascade comprises several related parallel pathways that activate a set of extracellular regulated kinase 1/2, JNK1/2, p38a/b/g/d or extracellular regulated kinase 5.(8) Although growth and inflammation can activate different amounts of these events, however, RAS is highly co…”
BackgroundGenome-wide association between YAP/TAZ/TEAD and AP-1 at enhancers drives oncogenic growth
Zanconato, F., Forcato, M., Battilana, G., Azzolin, L., Quaranta, E., Bodega, B., Rosato, A., Bicciato, S., Cordenonsi, M., & Piccolo, S. (2015) · Nature Cell Biology · doi:10.1038/ncb3216 · Cited by 1,219
TAZ, a Transcriptional Modulator of Mesenchymal Stem Cell Differentiation
Hong, J.-H., Hwang, E. S., McManus, M. T., Amsterdam, A., Tian, Y., Kalmukova, R., Mueller, E., Benjamin, T., Spiegelman, B. M., Sharp, P. A., et al. (2005) · Science · doi:10.1126/science.1110955 · Cited by 1,009
KRAS and YAP1 Converge to Regulate EMT and Tumor Survival
Shao, D. D., Xue, W., Krall, E. B., Bhutkar, A., Piccioni, F., Wang, X., Schinzel, A. C., Sood, S., Rosenbluh, J., Kim, J. W., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.004 · Cited by 744
Vassilev, A., Kaneko, K. J., Shu, H., Zhao, Y., & DePamphilis, M. L. (2001) · Genes & Development · doi:10.1101/gad.888601 · Cited by 719
Yap1 Activation Enables Bypass of Oncogenic Kras Addiction in Pancreatic Cancer
Kapoor, A., Yao, W., Ying, H., Hua, S., Liewen, A., Wang, Q., Zhong, Y., Wu, C.-J., Sadanandam, A., Hu, B., et al. (2014) · Cell · doi:10.1016/j.cell.2014.06.003 · Cited by 716
Mutant p53 drives metastasis and overcomes growth arrest/senescence in pancreatic cancer
Morton, J. P., Timpson, P., Karim, S. A., Ridgway, R. A., Athineos, D., Doyle, B., Jamieson, N. B., Oien, K. A., Lowy, A. M., Brunton, V. G., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0908428107 · Cited by 657
The Salvador–Warts–Hippo pathway — an emerging tumour-suppressor network
Harvey, K., & Tapon, N. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2070 · Cited by 628 · cited 1×
“phosphorylation pathway is the co-factor yes-associated protein (YAP) (dmYki) that participates in various activities (biological responses associated with different transcription factors).(26) The number of inputs of cell polarity regulators (Crumbs, Fat, Par 6/aPkc) and FERM domains upstream signal inducer proteins…”
BackgroundThe Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Lin, L., Sabnis, A. J., Chan, E., Olivas, V., Cade, L., Pazarentzos, E., Asthana, S., Neel, D., Yan, J. J., Lu, X., et al. (2015) · Nature Genetics · doi:10.1038/ng.3218 · Cited by 551
AMPK modulates Hippo pathway activity to regulate energy homeostasis
Wang, W., Xiao, Z.-D., Li, X., Aziz, K. E., Gan, B., Johnson, R. L., & Chen, J. (2015) · Nature Cell Biology · doi:10.1038/ncb3113 · Cited by 549
Morin-Kensicki, E. M., Boone, B. N., Howell, M., Stonebraker, J. R., Teed, J., Alb, J. G., Magnuson, T. R., O'Neal, W., & Milgram, S. L. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.1.77-87.2006 · Cited by 429
Er, E. E., Valiente, M., Ganesh, K., Zou, Y., Agrawal, S., Hu, J., Griscom, B., Rosenblum, M., Boire, A., Brogi, E., et al. (2018) · Nature Cell Biology · doi:10.1038/s41556-018-0138-8 · Cited by 292
YAP Drives Growth by Controlling Transcriptional Pause Release from Dynamic Enhancers
Galli, G. G., Carrara, M., Yuan, W.-C., Valdes-Quezada, C., Gurung, B., Pepe-Mooney, B., Zhang, T., Geeven, G., Gray, N. S., de Laat, W., et al. (2015) · Molecular Cell · doi:10.1016/j.molcel.2015.09.001 · Cited by 290
Regulation of TEAD Transcription Factors in Cancer Biology
Huh, H., Kim, D., Jeong, H.-S., & Park, H. (2019) · Cells · doi:10.3390/cells8060600 · Cited by 259
YAP-Induced PD-L1 Expression Drives Immune Evasion in BRAFi-Resistant Melanoma
Kim, M. H., Kim, C. G., Kim, S.-K., Shin, S. J., Choe, E. A., Park, S.-H., Shin, E.-C., & Kim, J. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0320 · Cited by 241
SOX2 Regulates YAP1 to Maintain Stemness and Determine Cell Fate in the Osteo-Adipo Lineage
Seo, E., Basu-Roy, U., Gunaratne, P. H., Coarfa, C., Lim, D.-S., Basilico, C., & Mansukhani, A. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.05.029 · Cited by 216
Hansen, C. G., Ng, Y. L. D., Lam, W.-L. M., Plouffe, S. W., & Guan, K.-L. (2015) · Cell Research · doi:10.1038/cr.2015.140 · Cited by 212
Lee, D.-H., Park, J. O., Kim, T.-S., Kim, S.-K., Kim, T.-H., Kim, M.-C., Park, G. S., Kim, J.-H., Kuninaka, S., Olson, E. N., et al. (2016) · Nature Communications · doi:10.1038/ncomms11961 · Cited by 196
Bile Acids Activate YAP to Promote Liver Carcinogenesis
Anakk, S., Bhosale, M., Schmidt, V. A., Johnson, R. L., Finegold, M. J., & Moore, D. D. (2013) · Cell Reports · doi:10.1016/j.celrep.2013.10.030 · Cited by 196
SRC tyrosine kinase activates the YAP/TAZ axis and thereby drives tumor growth and metastasis
Lamar, J. M., Xiao, Y., Norton, E., Jiang, Z.-G., Gerhard, G. M., Kooner, S., Warren, J. S. A., & Hynes, R. O. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.004364 · Cited by 169
Opposing activities of the Ras and Hippo pathways converge on regulation of YAP protein turnover
Hong, X., Nguyen, H. T., Chen, Q., Zhang, R., Hagman, Z., Voorhoeve, P. M., & Cohen, S. M. (2014) · The EMBO Journal · doi:10.15252/embj.201489385 · Cited by 121 · cited 1×
“Free cytoplasmic YAP is degraded by the ubiquitin ligase bTrCP-SCF complex, which in the presence of RAS, decreases the ligase targeting compounds and thereby increases YAP stability.(87) Thus, active RAS can increase YAP levels independently of Hippo, which required for RAS-induced tumorigenesis.”
BackgroundMRTF potentiates TEAD‐YAP transcriptional activity causing metastasis
Kim, T., Hwang, D., Lee, D., Kim, J., Kim, S., & Lim, D. (2017) · The EMBO Journal · doi:10.15252/embj.201695137 · Cited by 114
JNK signaling is converted from anti- to pro-tumor pathway by Ras-mediated switch of Warts activity
Enomoto, M., Kizawa, D., Ohsawa, S., & Igaki, T. (2015) · Developmental Biology · doi:10.1016/j.ydbio.2015.05.001 · Cited by 74 · cited 1×
“Recent studies suggest that this pathway regulates Ajuba by JNK (Lim protein domain), increased actin f, increased MST1/2, decreased activation of the Hippo pathway and YAP transduction from the nucleus.(72) JNK also inhibits YAP activity, whereby, YAP directly phosphorylated by JNK and leads to apoptosis by p73.”
Background
Research works printed but not linked: 157
- Bronte, 2015, New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?, Oncotarget, 6, 24780, 10.18632/oncotarget.4959 · DOI · Paper page
- Kranenburg, 2001, Ras-MAP kinase signaling by lysophosphatidic acid and other G protein-coupled receptor agonists, Oncogene, 20, 1540, 10.1038/sj.onc.1204187 · DOI · Paper page
- Magalhaes, 2012, Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins, Br J Pharmacol, 165, 1717, 10.1111/j.1476-5381.2011.01552.x · DOI · Paper page
- Ratner, 2015, A RASopathy gene commonly mutated in cancer: the neurofibromatosis type 1 tumour suppressor, Nat Rev Cancer, 15, 290, 10.1038/nrc3911 · DOI · Paper page
- Raaijmakers, 2009, Specificity in Ras and Rap signaling, J Biol Chem, 284, 10995, 10.1074/jbc.R800061200 · DOI · Paper page
- Chan, 2013, PLCϵ and the RASSF family in tumour suppression and other functions, Adv Biol Res, 53, 258
- Brown, 2009, Protein scaffolds in MAP kinase signalling, Cell Signal, 21, 462, 10.1016/j.cellsig.2008.11.013 · DOI · Paper page
- Claperon, 2007, KSR and CNK: two scaffolds regulating RAS-mediated RAF activation, Oncogene, 26, 3143, 10.1038/sj.onc.1210408 · DOI
- White, 2009, IQGAPs in cancer: a family of scaffold proteins underlying tumorigenesis, FEBS Lett, 583, 1817, 10.1016/j.febslet.2009.05.007 · DOI · Paper page
- Teis, 2006, p14-MP1-MEK1 signaling regulates endosomal traffic and cellular proliferation during tissue homeostasis, J Cell Biol, 175, 861, 10.1083/jcb.200607025 · DOI · Paper page
- Romano, 2014, Protein interaction switches coordinate Raf-1 and MST2/Hippo signalling, Nat Cell Biol, 16, 673, 10.1038/ncb2986 · DOI
- Dhomen, 2007, New insight into BRAF mutations in cancer, Curr Opin Genet Dev, 17, 31, 10.1016/j.gde.2006.12.005 · DOI · Paper page
- Hafner, 2010, Multiple oncogenic mutations and clonal relationship in spatially distinct benign human epidermal tumors, Proc Natl Acad Sci USA, 107, 20780, 10.1073/pnas.1008365107 · DOI
- Junttila, 2010, Selective activation of p53-mediated tumour suppression in high-grade tumours, Nature, 468, 567, 10.1038/nature09526 · DOI · Paper page
- Feldser, 2010, Stage-specific sensitivity to p53 restoration during lung cancer progression, Nature, 468, 572, 10.1038/nature09535 · DOI · Paper page
- Tan, 2014, Functions of TAp63 and p53 in restraining the development of metastatic cancer, Oncogene, 33, 3325, 10.1038/onc.2013.287 · DOI · Paper page
- Oren, 2010, Mutant p53 gain-of-function in cancer, Cold Spring Harb Perspect Biol, 2, 10.1101/cshperspect.a001107 · DOI · Paper page
- Irvine, 2015, Control of organ growth by patterning and hippo signaling in Drosophila, Cold Spring Harb Perspect Biol, 7, 10.1101/cshperspect.a019224 · DOI · Paper page
- Rawat, 2015, Regulation of mammalian Ste20 (mst) kinases, Trends Biochem Sci, 40, 149, 10.1016/j.tibs.2015.01.001 · DOI · Paper page
- Couzens, 2013, Protein interaction network of the mammalian Hippo pathway reveals mechanisms of kinase-phosphatase interactions, Sci Signal, 6, 10.1126/scisignal.2004712 · DOI · Paper page
- Hamilton, 2009, ATM regulates a RASSF1A-dependent DNA damage response, Curr Biol, 19, 2020, 10.1016/j.cub.2009.10.040 · DOI
- Avruch, 2009, Rassf family of tumor suppressor polypeptides, J Biol Chem, 284, 11001, 10.1074/jbc.R800073200 · DOI · Paper page
- Bayram, 2014, Association between RASSF1A Ala133Ser polymorphism and cancer susceptibility: a meta-analysis involving 8,892 subjects, Asian Pac J Cancer Prev APJCP, 15, 3691, 10.7314/APJCP.2014.15.8.3691 · doi:10.7314/apjcp.2014.15.8.3691
- Wu, 2010, Genome-wide interrogation identifies YAP1 variants associated with survival of small-cell lung cancer patients, Cancer Res, 70, 9721, 10.1158/0008-5472.CAN-10-1493 · DOI
- Yuan, 2015, Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival, Int J Cancer, 137, 638, 10.1002/ijc.29429 · DOI
- van der Weyden, 2012, Loss of RASSF1A synergizes with deregulated RUNX2 signaling in tumorigenesis, Cancer Res, 72, 3817, 10.1158/0008-5472.CAN-11-3343 · DOI
- Matallanas, 2007, RASSF1A elicits apoptosis through an MST2 pathway directing proapoptotic transcription by the p73 tumor suppressor protein, Mol Cell, 27, 962, 10.1016/j.molcel.2007.08.008 · DOI · Paper page
- Harvey, 2013, The Hippo pathway and human cancer, Nat Rev Cancer, 13, 246, 10.1038/nrc3458 · DOI · Paper page
- Matallanas, 2011, Mutant K-Ras activation of the proapoptotic MST2 pathway is antagonized by wild-type K-Ras, Mol Cell, 44, 893, 10.1016/j.molcel.2011.10.016 · DOI
- Takahashi, 2005, Down-regulation of LATS1 and LATS2 mRNA expression by promoter hypermethylation and its association with biologically aggressive phenotype in human breast cancers, Clin Cancer Res, 11, 1380, 10.1158/1078-0432.CCR-04-1773 · DOI · Paper page
- Seidel, 2007, Frequent hypermethylation of MST1 and MST2 in soft tissue sarcoma, Mol Carcinog, 46, 865, 10.1002/mc.20317 · DOI · Paper page
- Grawenda, 2015, Clinical utility of RASSF1A methylation in human malignancies, Br J Canc, 113, 372, 10.1038/bjc.2015.221 · DOI
- Vlahov, 2015, Alternate RASSF1 transcripts control SRC activity, E-cadherin contacts, and YAP-mediated invasion, Curr Biol, 25, 3019, 10.1016/j.cub.2015.09.072 · DOI
- Gregorieff, 2015, Yap-dependent reprogramming of Lgr5(+) stem cells drives intestinal regeneration and cancer, Nature, 526, 715, 10.1038/nature15382 · DOI · Paper page
- Gordon, 2013, The tumor suppressor gene, RASSF1A, is essential for protection against inflammation -induced injury, PLoS One, 8, 10.1371/journal.pone.0075483 · DOI
- Halder, 2011, Hippo signaling: growth control and beyond, Development, 138, 9, 10.1242/dev.045500 · DOI · Paper page
- Zhang, 2014, Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma, Sci Signal, 7, 10.1126/scisignal.2005049 · DOI · Paper page
- Avruch, 2012, Protein kinases of the Hippo pathway: regulation and substrates, Semin Cell Dev Biol, 23, 770, 10.1016/j.semcdb.2012.07.002 · DOI · Paper page
- O'Neill, 2004, Role of the kinase MST2 in suppression of apoptosis by the proto-oncogene product Raf-1, Science, 306, 2267, 10.1126/science.1103233 · DOI · Paper page
- Volodko, 2014, RASSF tumor suppressor gene family: biological functions and regulation, FEBS Lett, 588, 2671, 10.1016/j.febslet.2014.02.041 · DOI · Paper page
- Polesello, 2006, The Drosophila RASSF homolog antagonizes the hippo pathway, Curr Biol, 16, 2459, 10.1016/j.cub.2006.10.060 · DOI · Paper page
- Avruch, 2006, Nore1 and RASSF1 regulation of cell proliferation and of the MST1/2 kinases, Methods Enzymol, 407, 290, 10.1016/S0076-6879(05)07025-4 · DOI
- Yu, 2015, Cardiac hypertrophy induced by active Raf depends on Yorkie-mediated transcription, Sci Signal, 8, 10.1126/scisignal.2005719 · DOI
- Tapon, 2002, Salvador Promotes both cell cycle exit and apoptosis in Drosophila and is mutated in human cancer cell lines, Cell, 110, 467, 10.1016/S0092-8674(02)00824-3 · DOI · Paper page
- Rushworth, 2006, Regulation and role of Raf-1/B-Raf heterodimerization, Mol Cell Biol, 26, 2262, 10.1128/MCB.26.6.2262-2272.2006 · DOI · Paper page
- Hergovich, 2009, Mammalian NDR/LATS protein kinases in hippo tumor suppressor signaling, Biofactors, 35, 338, 10.1002/biof.47 · DOI
- Muller-Taubenberger, 2014, Regulation of a LATS-homolog by Ras GTPases is important for the control of cell division, BMC Cell Biol, 15, 10.1186/1471-2121-15-25 · DOI
- Anguera, 2008, Characterization of two Mst1-deficient mouse models, Dev Dynam, 237, 3424, 10.1002/dvdy.21764 · DOI
- Oh, 2009, Crucial role for Mst1 and Mst2 kinases in early embryonic development of the mouse, Mol Cell Biol, 29, 6309, 10.1128/MCB.00551-09 · DOI · Paper page
- Du, 2014, Mst1 and mst2 are essential regulators of trophoblast differentiation and placenta morphogenesis, PLoS One, 9, 10.1371/journal.pone.0090701 · DOI
- St John, 1999, Mice deficient of Lats1 develop soft-tissue sarcomas, ovarian tumours and pituitary dysfunction, Nat Genet, 21, 182, 10.1038/5965 · DOI · Paper page
- McPherson, 2004, Lats2/Kpm is required for embryonic development, proliferation control and genomic integrity, EMBO J, 23, 3677, 10.1038/sj.emboj.7600371 · DOI · Paper page
- Das Thakur, 2010, Ajuba LIM proteins are negative regulators of the Hippo signaling pathway, Curr Biol, 20, 657, 10.1016/j.cub.2010.02.035 · DOI · Paper page
- Sun, 2013, Ajuba family proteins link JNK to Hippo signaling, Sci Signal, 6, 10.1126/scisignal.2004324 · DOI · Paper page
- Reddy, 2013, Regulation of Hippo signaling by EGFR-MAPK signaling through Ajuba family proteins, Dev Cell, 24, 459, 10.1016/j.devcel.2013.01.020 · DOI · Paper page
- Graves, 1998, Caspase-mediated activation and induction of apoptosis by the mammalian Ste20-like kinase Mst1, EMBO J, 17, 2224, 10.1093/emboj/17.8.2224 · DOI · Paper page
- Graves, 2001, Both phosphorylation and caspase-mediated cleavage contribute to regulation of the Ste20-like protein kinase Mst1 during CD95/Fas-induced apoptosis, J Biol Chem, 276, 14909, 10.1074/jbc.M010905200 · DOI · Paper page
- Ura, 2007, Activation of the c-Jun N-terminal kinase pathway by MST1 is essential and sufficient for the induction of chromatin condensation during apoptosis, Mol Cell Biol, 27, 5514, 10.1128/MCB.00199-07 · DOI
- Densham, 2009, MST kinases monitor actin cytoskeletal integrity and signal via c-Jun N-terminal kinase stress-activated kinase to regulate p21Waf1/Cip1 stability, Mol Cell Biol, 29, 6380, 10.1128/MCB.00116-09 · DOI · Paper page
- Danovi, 2008, Yes-associated protein (YAP) is a critical mediator of c-Jun-dependent apoptosis, Cell Death Differ, 15, 217, 10.1038/sj.cdd.4402226 · DOI
- Tomlinson, 2010, JNK phosphorylates Yes-associated protein (YAP) to regulate apoptosis, Cell Death Dis, 1, 10.1038/cddis.2010.7 · DOI · Paper page
- Genevet, 2011, The Hippo pathway and apico-basal cell polarity, Biochem J, 436, 213, 10.1042/BJ20110217 · DOI · Paper page
- Yang, 2014, Phosphorylation of KIBRA by the extracellular signal-regulated kinase (ERK)-ribosomal S6 kinase (RSK) cascade modulates cell proliferation and migration, Cell Signal, 26, 343, 10.1016/j.cellsig.2013.11.012 · DOI
- Hilton, 2008, KIBRA interacts with discoidin domain receptor 1 to modulate collagen-induced signalling, Biochim Biophys Acta, 1783, 383, 10.1016/j.bbamcr.2007.12.007 · DOI
- Heidary Arash, 2014, Arhgef7 promotes activation of the Hippo pathway core kinase Lats, EMBO J, 33, 2997, 10.15252/embj.201490230 · DOI · Paper page
- Zhang, 2009, YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway, Nat Cell Biol, 11, 1444, 10.1038/ncb1993 · DOI · Paper page
- Kim, 2013, cAMP/PKA signalling reinforces the LATS-YAP pathway to fully suppress YAP in response to actin cytoskeletal changes, EMBO J, 32, 1543, 10.1038/emboj.2013.102 · DOI · Paper page
- Yu, 2013, Protein kinase A activates the Hippo pathway to modulate cell proliferation and differentiation, Genes Dev, 27, 1223, 10.1101/gad.219402.113 · DOI · Paper page
- Dumaz, 2005, Integrating signals between cAMP and the RAS/RAF/MEK/ERK signaling pathways. Based on the anniversary prize of the Gesellschaft Fur Biochemie und Molekularbiologie Lecture delivered on 5 July 2003 at the Special FEBS Meeting in Brussels, FEBS J, 272, 3491, 10.1111/j.1742-4658.2005.04763.x · DOI · Paper page
- Mauviel, 2012, Integrating developmental signals: a Hippo in the (path) way, Oncogene, 31, 1743, 10.1038/onc.2011.363 · DOI
- Dong, 2007, Elucidation of a universal size-control mechanism in Drosophila and mammals, Cell, 130, 1120, 10.1016/j.cell.2007.07.019 · DOI · Paper page
- Xin, 2011, Regulation of insulin-like growth factor signaling by Yap governs cardiomyocyte proliferation and embryonic heart size, Sci Signal, 4, 10.1126/scisignal.2002278 · DOI · Paper page
- He, 2015, The Hippo/YAP pathway interacts with EGFR signaling and HPV oncoproteins to regulate cervical cancer progression, EMBO Mol Med, 7, 1426, 10.15252/emmm.201404976 · DOI · Paper page
- Garcia-Rendueles, 2015, NF2 loss promotes oncogenic RAS-induced thyroid cancers via YAP-dependent transactivation of RAS proteins and sensitizes them to MEK inhibition, Cancer Discov, 5, 1178, 10.1158/2159-8290.CD-15-0330 · DOI · Paper page
- Harris, 2010, The molecular pathology of cancer, Nat Rev Clin Oncol, 7, 251, 10.1038/nrclinonc.2010.41 · DOI · Paper page
- Zinatizadeh, 2019, The Role and Function of Ras-association domain family in Cancer: A Review, Genes Dis, 6, 378, 10.1016/j.gendis.2019.07.008 · DOI
- Yasunami, 1996, A novel family of TEA domain-containing transcription factors with distinct spatiotemporal expression patterns, Biochem Biophys Res Commun, 228, 365, 10.1006/bbrc.1996.1667 · DOI
- Lin, 2017, Regulation of the hippo pathway transcription factor TEAD, Trends Biochem Sci, 42, 862, 10.1016/j.tibs.2017.09.003 · DOI · Paper page
- Chen, 1994, Transcriptional enhancer factor-1 disruption by a retroviral gene trap leads to heart-defects and embryonic lethality in mice, Genes Dev, 8, 2293, 10.1101/gad.8.19.2293 · DOI · Paper page
- Kaneko, 2007, Transcription factor TEAD2 is involved in neural tube closure, Genesis, 45, 577, 10.1002/dvg.20330 · DOI · Paper page
- Sawada, 2008, Redundant roles of Tead1 and Tead2 in notochord development and the regulation of cell proliferation and survival, Mol Cell Biol, 28, 3177, 10.1128/MCB.01759-07 · DOI · Paper page
- Yagi, 2007, Transcription factor TEAD4 specifies the trophectoderm lineage at the beginning of mammalian development, Development, 134, 3827, 10.1242/dev.010223 · DOI · Paper page
- Nishioka, 2008, Tead4 is required for specification of trophectoderm in pre-implantation mouse embryos, Mech Dev, 125, 270, 10.1016/j.mod.2007.11.002 · DOI · Paper page
- Nishioka, 2009, The Hippo signaling pathway components Lats and Yap pattern Tead4 activity to distinguish mouse trophectoderm from inner cell mass, Dev Cell, 16, 398, 10.1016/j.devcel.2009.02.003 · DOI · Paper page
- Ota, 2008, Mammalian Tead proteins regulate cell proliferation and contact inhibition as transcriptional mediators of Hippo signaling, Development, 135, 4059, 10.1242/dev.027151 · DOI · Paper page
- Jacquemin, 1996, A novel family of developmentally regulated mammalian transcription factors containing the TEA/ATTS DNA binding domain, J Biol Chem, 271, 21775, 10.1074/jbc.271.36.21775 · DOI · Paper page
- Jiang, 2000, Cooperative binding of TEF-1 to repeated GGAATG-related consensus elements with restricted spatial separation and orientation, DNA Cell Biol, 19, 507, 10.1089/10445490050128430 · DOI · Paper page
- Anbanandam, 2006, Insights into transcription enhancer factor 1 (TEF-1) activity from the solution structure of the TEA domain, Proc Natl Acad Sci USA, 103, 17225, 10.1073/pnas.0607171103 · DOI · Paper page
- Li, 2015, Proteomic analyses reveal distinct chromatin-associated and soluble transcription factor complexes, Mol Syst Biol, 11, 10.15252/msb.20145504 · DOI · Paper page
- Xiao, 1991, Cloning, expression, and transcriptional properties of the human enhancer factor tef-1, Cell, 65, 551, 10.1016/0092-8674(91)90088-G · DOI · Paper page
- Zhang, 2009, TEAD transcription factors mediate the function of TAZ in cell growth and epithelial-mesenchymal transition, J Biol Chem, 284, 13355, 10.1074/jbc.M900843200 · DOI · Paper page
- Mahoney, 2005, The transcriptional co-activator TAZ interacts differentially with transcriptional enhancer factor-1 (TEF-1) family members, Biochem J, 388, 217, 10.1042/BJ20041434 · DOI · Paper page
- Chen, 2004, Transcription cofactor Vgl-2 is required for skeletal muscle differentiation, Genesis, 39, 273, 10.1002/gene.20055 · DOI
- Koontz, 2013, The hippo Eector Yorkie controls normal tissue growth by antagonizing scalloped-mediated default repression, Dev Cell, 25, 388, 10.1016/j.devcel.2013.04.021 · DOI · Paper page
- Chen, 2004, Vgl-4, a novel member of the vestigial-like family of transcription cofactors, regulates alpha1-adrenergic activation of gene expression in cardiac myocytes, J Biol Chem, 279, 30800, 10.1074/jbc.M400154200 · DOI · Paper page
- Pobbati, 2012, Structural and functional similarity between the Vgll1-TEAD and the YAP-TEAD complexes, Structure, 20, 1135, 10.1016/j.str.2012.04.004 · DOI · Paper page
- Honda, 2017, Vestigial-like 2 contributes to normal muscle fiber type distribution in mice, Sci Rep, 7, 10.1038/s41598-017-07149-0 · DOI
- Figeac, 2019, VGLL3 operates via TEAD1, TEAD3 and TEAD4 to influence myogenesis in skeletal muscle, J Cell Sci, 132, 10.1242/jcs.225946 · DOI
- Kim, 2015, Transcriptional Co-repressor function of the hippo pathway transducers YAP and TAZ, Cell Rep, 11, 270, 10.1016/j.celrep.2015.03.015 · DOI · Paper page
- Jiao, 2017, VGLL4 targets a TCF4-TEAD4 complex to coregulate Wnt and Hippo signalling in colorectal cancer, Nat Commun, 8, 10.1038/ncomms14058 · DOI · Paper page
- Beyer, 2013, Switch enhancers interpret TGF-beta and Hippo signaling to control cell fate in human embryonic stem cells, Cell Rep, 5, 1611, 10.1016/j.celrep.2013.11.021 · DOI · Paper page
- Liu, 2016, Tead and AP1 coordinate transcription and motility, Cell Rep, 14, 1169, 10.1016/j.celrep.2015.12.104 · DOI · Paper page
- Park, 2015, Alternative Wnt signaling activates YAP/TAZ, Cell, 162, 780, 10.1016/j.cell.2015.07.013 · DOI · Paper page
- Lai, 2013, BMP4 is a novel transcriptional target and mediator of mammary cell migration downstream of the Hippo pathway component TAZ, Cell Signal, 25, 1720, 10.1016/j.cellsig.2013.05.002 · DOI
- Zhang, 2009, YAP-dependent induction of amphiregulin identifies a non-cell-autonomous component of the Hippo pathway, Nat Cell Biol, 11, 1444, 10.1038/ncb1993 · DOI · Paper page
- Song, 2015, The hippo coactivator YAP1 mediates EGFR overexpression and confers chemoresistance in esophageal cancer, Clin Cancer Res, 21, 2580, 10.1158/1078-0432.CCR-14-2191 · DOI · Paper page
- Feng, 2017, Tumor cell-derived lactate induces TAZ-dependent upregulation of PD-L1 through GPR81 in human lung cancer cells, Oncogene, 36, 5829, 10.1038/onc.2017.188 · DOI · Paper page
- Van Rensburg, 2018, The hippo pathway component TAZ promotes immune evasion in human cancer through PD-L1, Cancer Res, 78, 1457, 10.1158/0008-5472.CAN-17-3139 · DOI · Paper page
- Miao, 2017, YAP regulates PD-L1 expression in human NSCLC cells, Oncotarget, 8, 114576, 10.18632/oncotarget.23051 · DOI · Paper page
- Neto-Silva, 2010, Evidence for a growth-stabilizing regulatory feedback mechanism between Myc and Yorkie, the Drosophila homolog of Yap, Dev Cell, 19, 507, 10.1016/j.devcel.2010.09.009 · DOI · Paper page
- Rajbhandari, 2018, Cross-cohort analysis identifies a TEAD4-MYCN positive feedback loop as the core regulatory element of high-risk neuroblastoma, Cancer Discov, 8, 582, 10.1158/2159-8290.CD-16-0861 · DOI · Paper page
- Moroishi, 2015, A YAP/TAZ-induced feedback mechanism regulates Hippo pathway homeostasis, Genes Dev, 29, 1271, 10.1101/gad.262816.115 · DOI · Paper page
- Park, 2016, Yes-associated protein 1 and transcriptional coactivator with PDZ-binding motif activate the mammalian target of rapamycin complex 1 pathway by regulating amino acid transporters in hepatocellular carcinoma, Hepatology, 63, 159, 10.1002/hep.28223 · DOI · Paper page
- Holden, 2018, Targeting the hippo pathway and cancer through the TEAD family of transcription factors, Cancers, 10, 10.3390/cancers10030081 · DOI · Paper page
- Pobbati, 2013, Emerging roles of TEAD transcription factors and its coactivators in cancers, Cancer Biol Ther, 14, 390, 10.4161/cbt.23788 · DOI · Paper page
- Knight, 2008, TEAD1 and c-Cbl are novel prostate basal cell markers that correlate with poor clinical outcome in prostate cancer, Br J Canc, 99, 1849, 10.1038/sj.bjc.6604774 · DOI
- Liang, 2014, Expression of hippo pathway in colorectal cancer, Saudi J Gastroenterol, 20, 188, 10.4103/1319-3767.133025 · DOI · Paper page
- Liu, 2016, Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner, Oncogene, 35, 2789, 10.1038/onc.2015.342 · DOI
- Zhou, 2017, TEAD1/4 exerts oncogenic role and is negatively regulated by miR-4269 in gastric tumorigenesis, Oncogene, 36, 6518, 10.1038/onc.2017.257 · DOI
- Zhou, 2013, Effects of the hippo signaling pathway in human gastric cancer, Asian Pac J Cancer Prev APJCP, 14, 5199, 10.7314/APJCP.2013.14.9.5199 · DOI
- Han, 2008, DNA copy number alterations and expression of relevant genes in triple-negative breast cancer, Genes Chromosomes Cancer, 47, 490, 10.1002/gcc.20550 · DOI
- Wang, 2015, The interplay between TEAD4 and KLF5 promotes breast cancer partially through inhibiting the transcription of p27(Kip1), Oncotarget, 6, 17685, 10.18632/oncotarget.3779 · DOI
- Korkola, 2006, Down-regulation of stem cell genes, including those in a 200-kb gene cluster at 12p13.31, is associated with in vivo dierentiation of human male germ cell tumors, Cancer Res, 66, 820, 10.1158/0008-5472.CAN-05-2445 · DOI · Paper page
- Skotheim, 2006, Novel genomic aberrations in testicular germ cell tumors by array-CGH, and associated gene expression changes, Cell Oncol, 28, 315
- Zhang, 2018, TEAD4 overexpression promotes epithelial-mesenchymal transition and associates with aggressiveness and adverse prognosis in head neck squamous cell carcinoma, Cancer Cell Int, 18, 10.1186/s12935-018-0675-z · DOI
- Schutte, 2014, Hippo signaling mediates proliferation, invasiveness, and metastatic potential of clear cell renal cell carcinoma, Transl Oncol, 7, 309, 10.1016/j.tranon.2014.02.005 · DOI · Paper page
- Fernandez-L, 2009, YAP1 is amplified and up-regulated in hedgehog-associated medulloblastomas and mediates Sonic hedgehog-driven neural precursor proliferation, Genes Dev, 23, 2729, 10.1101/gad.1824509 · DOI · Paper page
- Bokhovchuk, 2019, Molecular and structural characterization of a TEAD mutation at the origin of Sveinsson's chorioretinal atrophy, FEBS J, 286, 2381, 10.1111/febs.14817 · DOI
- Fossdal, 2004, A novel TEAD1 mutation is the causative allele in Sveinsson's chorioretinal atrophy (helicoid peripapillary chorioretinal degeneration), Hum Mol Genet, 13, 975, 10.1093/hmg/ddh106 · DOI · Paper page
- Sun, 2015, Prognostic Value of yes-associated protein 1 (YAP1) in various cancers: a meta-analysis, PLoS One, 10, 10.1371/journal.pone.0135119 · DOI
- Feng, 2016, Prognostic significance of TAZ expression in various cancers: a meta-analysis, OncoTargets Ther, 9, 5235, 10.2147/OTT.S109540 · DOI
- Jiao, 2014, A peptide mimicking VGLL4 function acts as a YAP antagonist therapy against gastric cancer, Cancer Cell, 25, 166, 10.1016/j.ccr.2014.01.010 · DOI · Paper page
- Park, 2013, Regulation of the Hippo pathway and implications for anticancer drug development, Trends Pharmacol Sci, 34, 581, 10.1016/j.tips.2013.08.006 · DOI · Paper page
- Haemmerle, 2017, Platelets reduce anoikis and promote metastasis by activating YAP1 signaling, Nat Commun, 8, 10.1038/s41467-017-00411-z · DOI · Paper page
- Zhao, 2012, Cell detachment activates the Hippo pathway via cytoskeleton reorganization to induce anoikis, Genes Dev, 26, 54, 10.1101/gad.173435.111 · DOI · Paper page
- Lee, 2017, Fluid shear stress activates YAP1 to promote cancer cell motility, Nat Commun, 8
- Chen, 2012, LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker, Nat Med, 18, 1511, 10.1038/nm.2940 · DOI · Paper page
- Guo, 2016, RAR gamma downregulation contributes to colorectal tumorigenesis and metastasis by derepressing the hippo-Yap pathway, Cancer Res, 76, 3813, 10.1158/0008-5472.CAN-15-2882 · DOI · Paper page
- Li, 2017, A ROR1-HER3-lncRNA signalling axis modulates the Hippo-YAP pathway to regulate bone metastasis, Nat Cell Biol, 19, 106, 10.1038/ncb3464 · DOI · Paper page
- Qiao, 2017, YAP regulates actin dynamics through ARHGAP29 and promotes metastasis, Cell Rep, 19, 1495, 10.1016/j.celrep.2017.04.075 · DOI · Paper page
- Lee, 2017, YAP1 is essential for tumor growth and is a potential therapeutic target for EGFR-dependent lung adenocarcinomas, Oncotarget, 8, 89539, 10.18632/oncotarget.19647 · DOI
- Lee, 2018, Enhanced YAP expression leads to EGFR TKI resistance in lung adenocarcinomas, Sci Rep, 8, 271, 10.1038/s41598-017-18527-z · DOI · Paper page
- Xu, 2015, Up-regulation of the Hippo pathway effector TAZ renders lung adenocarcinoma cells harboring EGFR-T790M mutation resistant to gefitinib, Cell Biosci, 5, 10.1186/2045-3701-5-7 · DOI · Paper page
- Yamauchi, 2019, Hippo pathway in mammalian adaptive immune system, Cells, 8, 10.3390/cells8050398 · DOI
- Zhang, 2014, Downstream of mutant KRAS, the transcription regulator YAP is essential for neoplastic progression to pancreatic ductal adenocarcinoma, Sci Signal, 7, 10.1126/scisignal.2005049 · DOI · Paper page
- Rozengurt, 2018, Yes-associated protein (YAP) in pancreatic cancer: at the epicenter of a targetable signaling network associated with patient survival, Signal Transduct Targeted Ther, 3, 10.1038/s41392-017-0005-2 · DOI · Paper page
- Kapoor, 2014, Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer, Cell, 158, 185, 10.1016/j.cell.2014.06.003 · DOI · Paper page
- Davies, 2002, Mutations of the BRAF gene in human cancer, Nature, 417, 949, 10.1038/nature00766 · DOI · Paper page
- Hauschild, 2012, Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial, Lancet, 380, 358, 10.1016/S0140-6736(12)60868-X · DOI · Paper page
- Fisher, 2017, Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells, Oncotarget, 8, 110257, 10.18632/oncotarget.22628 · DOI
- Kim, 2016, Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation, EMBO J, 35, 462, 10.15252/embj.201592081 · DOI · Paper page
- Murakami, 2017, Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma, Oncogene, 36, 1232, 10.1038/onc.2016.288 · DOI · Paper page
- Feng, 2014, Hippo-independent activation of YAP by the GNAQ uveal melanoma oncogene through atrio-regulated rho GTPase signaling circuitry, Cancer Cell, 25, 831, 10.1016/j.ccr.2014.04.016 · DOI · Paper page
- Yu, 2014, Mutant Gq/11 promote uveal melanoma tumorigenesis by activating YAP, Cancer Cell, 25, 822, 10.1016/j.ccr.2014.04.017 · DOI · Paper page
- Garcia-Ocana, 2014, “RAS”ling beta cells to proliferate for diabetes: why do we need MEN?, J Clin Investig, 124, 3698, 10.1172/JCI77764 · DOI
- Chamberlain, 2014, Menin determines K-RAS proliferative outputs in endocrine cells, J Clin Investig, 124, 4093, 10.1172/JCI69004 · DOI
- Kok, 1997, Deletions of the short arm of chromosome 3 in solid tumors and the search for suppressor genes, Adv Cancer Res, 71, 27, 10.1016/S0065-230X(08)60096-2 · DOI · Paper page
Cited by
EGFR in Cancer: Signaling Mechanisms, Drugs, and Acquired Resistance
Uribe, M. L., Marrocco, I., & Yarden, Y. (2021) · Cancers · doi:10.3390/cancers13112748 · Cited by 604
The Nuclear Factor Kappa B (NF-kB) signaling in cancer development and immune diseases
Zinatizadeh, M. R., Schock, B., Chalbatani, G. M., Zarandi, P. K., Jalali, S. A., & Miri, S. R. (2021) · Genes & Diseases · doi:10.1016/j.gendis.2020.06.005 · Cited by 553
Self-citationInsights into recent findings and clinical application of YAP and TAZ in cancer
Franklin, J. M., Wu, Z., & Guan, K.-L. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00579-1 · Cited by 213
The Impact of Cancer Stem Cells in Colorectal Cancer
Radu, P., Zurzu, M., Tigora, A., Paic, V., Bratucu, M., Garofil, D., Surlin, V., Munteanu, A. C., Coman, I. S., Popa, F., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084140 · Cited by 30
Metadata
- Authors
- Zinatizadeh, M. R., Miri, S. R., Zarandi, P. K., Chalbatani, G. M., Rapôso, C., Mirzaei, H. R., Akbari, M. E., & Mahmoodzadeh, H.
- Venue
- Genes & Diseases
- Publisher
- Elsevier BV
- Published
- 2021-01
- Volume
- 8
- Issue
- 1
- Pages
- 48-60
- ISSN
- 2352-3042 (ISSN-L)
- OpenAlex
- W2992254622
- Cited by
- 94
- References
- 31
- FWCI
- 1.88
- Type
- journal article
- Language
- en
- Open access
- gold
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- www.elsevier.com/legal/tdmrep-license (tdm)
- creativecommons.org/licenses/by-nc-nd/4.0/ (vor)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.